

产品名称：西维来司他

产品别名：**Sivelestat**

生物活性:

| Description | Sivelestat(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat, hamster and mouse. IC50 value: 44 nM [1] Target: neutrophil elastase ONO-5046 did not inhibit trypsin, thrombin, plasmin, plasma kallikrein, pancreas kallikrein, chymotrypsin and cathepsin G even at 100 microM. In in vivo studies, ONO-5046 suppressed lung hemorrhage in hamster (ID50 = 82 micrograms/kg) by intratracheal administration and increase of skin capillary permeability in guinea pig (ID50 = 9.6 mg/kg) by intravenous administration, both of which were induced by human neutrophil elastase [1]. Sivelestat sodium hydrate is an anti-neutrophil elastase inhibitor and may be one of the treatment options for acute respiratory failure due to pneumocystis pneumonia in AIDS patients [2]. | | | | | | | | | | | | | | | | | | | | | | | | |
|-------------------------------|---|-----------|----------------|------------|-------|-------|---------------|--|--|--|-----------|------|-----------|------------|------------|-----------------|------|-----------|-----------|-----------|--|-------|-----------|-----------|-----------|
| Solvent&Solubility | <p>In Vitro:</p> <p>DMSO : \geq 100 mg/mL (230.17 mM)</p> <p>* "\geq" means soluble, but saturation unknown.</p> <table border="1" data-bbox="450 871 1356 1073"><thead><tr><th rowspan="2"></th><th>Solvent \ Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>Concentration</th><th></th><th></th><th></th></tr></thead><tbody><tr><th>Preparing</th><td>1 mM</td><td>2.3017 mL</td><td>11.5085 mL</td><td>23.0171 mL</td></tr><tr><th>Stock Solutions</th><td>5 mM</td><td>0.4603 mL</td><td>2.3017 mL</td><td>4.6034 mL</td></tr><tr><th></th><td>10 mM</td><td>0.2302 mL</td><td>1.1509 mL</td><td>2.3017 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。</p> <p>1. 请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline Solubility: \geq 2.5 mg/mL (5.75 mM); Clear solution 此方案可获得 \geq 2.5 mg/mL (5.75 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline) Solubility: \geq 2.5 mg/mL (5.75 mM); Clear solution 此方案可获得 \geq 2.5 mg/mL (5.75 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3. 请依序添加每种溶剂： 10% DMSO → 90% corn oil</p> | | Solvent \ Mass | 1 mg | 5 mg | 10 mg | Concentration | | | | Preparing | 1 mM | 2.3017 mL | 11.5085 mL | 23.0171 mL | Stock Solutions | 5 mM | 0.4603 mL | 2.3017 mL | 4.6034 mL | | 10 mM | 0.2302 mL | 1.1509 mL | 2.3017 mL |
| | Solvent \ Mass | | 1 mg | 5 mg | 10 mg | | | | | | | | | | | | | | | | | | | | |
| | Concentration | | | | | | | | | | | | | | | | | | | | | | | | |
| Preparing | 1 mM | 2.3017 mL | 11.5085 mL | 23.0171 mL | | | | | | | | | | | | | | | | | | | | | |
| Stock Solutions | 5 mM | 0.4603 mL | 2.3017 mL | 4.6034 mL | | | | | | | | | | | | | | | | | | | | | |
| | 10 mM | 0.2302 mL | 1.1509 mL | 2.3017 mL | | | | | | | | | | | | | | | | | | | | | |

| | |
|-------------------|--|
| | <p>Solubility: $\geq 2.5 \text{ mg/mL}$ (5.75 mM); Clear solution</p> <p>此方案可获得 $\geq 2.5 \text{ mg/mL}$ (5.75 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p> |
| References | <p>[1]. Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. <i>Biochem Biophys Res Commun.</i> 1991 Jun 14;177(2):814-20.</p> <p>[2]. Imokawa S, et al. Acute respiratory failure due to <i>pneumocystis pneumonia</i> successfully treated with combined use of sivelestat sodium hydrate. <i>Nihon Kokyuki Gakkai Zasshi.</i> 2008 Jun;46(6):461-5.</p> |



源叶生物